A small number of acylating agents are known to be carcinogenic. The structure-activity relationships and carcinogenicity (SARC) of these compounds are reviewed in this report. I n addition , the results of chronic bioassays of three previously untested compounds are described. Female ICR/Ha Swiss mice, 30-50 per group, were used in all tests. The test duration was 18-22 months. Diethylcarbamyl chloride (DECC), ethyl chloroformate (ECF), and dichloroacetyl chloride (DCAC) were tested by repeated skin application, in two-stage carcinogenesis with phorbol myristate acetate (PMA) as promoter, and by repeated subcutaneous injection. Dimethylcarbamyl chloride was used as a positive control together with control groups. All three compounds showed marginally significant incidences of papillomas and carcinomas when tested as initiators. ECF and DCAC did not show skin tumorigenicity in the repeated skin application tests. DECC showed weak carcinogenicity compared to DMCC. Subcutaneous injection resulted in the same pattern of tumorigenicity. Thus, the four acylating agents showed the following decreasing order of carcinogenicity: DMCC > DECC > ECF 2 DCAC. All four compounds hydrolyze rapidly in water, with the following decreasing order of rate of hydrolysis: DCAC > DMCC s ECF > DECC. Their mechanisms of hydrolysis are: DMCC, DECC, and DCAC, s N 1 ; ECF, s N 2 . There is no clear correlation between rate or mechanism of hydrolysis and carcinogenicity of these acylating agents.
VAN DUUREN ET AL. work from this Institute, DMCC was shown to induce squamous carcinoma of the skin in micc by topical application and fibrosarcomas by subcutanecus injection." 'I Inhalation exposure in hamsters(') and in rats'') resulted in tumors of the respiratory tract. Diethylcarbamyl chloride (DECC), a close analog of DMCC, was found to be a weaker carcinogen than DMCC on mouse skin and by subcutaneous injection in mice. The latter finding was published as a preliminary report.'"'
Our interest in and concern about acylating agents as potential carcinogens are uniquely demonstrated for DMCC. This compound is an acylating agent by virtue of the intermediacy of an acyliurn ion," 'I which accounts for its reactions with nucleophiles, such as purine and pyrimidine bases in DNA. Moreover, this acylium ion is in all likelihood in equilibrium with the quaternary iminium cation (Fig. I) , which has the structural features of an isocyanate, as in methyl isocyanate. The existence of such structures is of considerable interest in studies on structure-activity relationships of carcinogens (SARC) because of resonance stabilization. The latter chemical property is expected to have important biological implications, in this case cancer induction, as has been proposed for the very potent human and animal carcinogen, bis(chloromethyl)ether.(") Very few other acylating agents have been examined for carcinogenicity. Epidemiological data suggest that benzoyl chloride is an occupational carcinogen that causes lung cancer in workers exposed to it." "') Subsequent experiments showed that benzoyl chloride is a mouse skin carcinogen.'"' Resonance structures for dimethylcarbamyl chloride cations compared to parent com-
ACYLATING AGENT CARCINOGENS AND SARC
The present report reviews earlier work and describes the chronic bioassay of DECC, ethylchloroformate (ECF), and dichloroacetyl chloride (DCAC) in ICR/Ha mice. The structures of these and other compounds discussed in this report are shown in Figure 2 .
Three test protocols were used: repeated skin application of the chemical, two-stage skin carcinogenesis with phorbol myristate acetate (PMA) as promoter, and subcutaneous injection. In all these bioassays, DMCC served as a positive control. These findings are relevant to studies on SARC of these acylating agents and possibly to occupational cancer.
MATERIALS AND METHODS

Chemicak
The chemicals used in these bioassays, their sources, purity, and other pertinent information are given in Table 1 . Pure PMA was used as promoter.i1z' Reagent grade acetone (kept dry over adsorbent) and pure trioctanoin (Eastman Organic Chemicals, Rochester, NY) were used as vehicles. test (short-term or chronic) at 6-8 weeks of age, 7-14 days after arrival. The mice were housed in stainless steel cages (6 per cage) on hardwood chips and were fed Purina Rodent Chow and tap water ad libitum. The animal rooms were maintained at 22-24°C on a 12-hour dark, 12-hour light cycle with adequate fresh air supply of 10-12 air changes per hour. All treatments were done in ventilated treatment hoods having an air flow of at least 100 linear ft/min. After treatment, the mice were housed in these hoods for 2-3 hours before being returned to the animal rooms. Vehicle and untreated control mice were housed in the same room as treated mice.
Animals, housing, and maintenance
Chronic b ioassays
For all compounds, 6-to 8-week short-term toxicity tests were performed using five mice per dose level. In these short-term assays, three to five dose levels per chemical were used. The chronic bioassays were based on these short-term tests. The doses selected as maximum tolerated doses (MTD) for chronic bioassays were those that resulted in little or no inflammation at the site of administration, no clinically observable toxic effects, and normal weight gain for the duration of the short-term test. The chronic bioassays were conducted for 18-22 months at the doses shown in Table 2 . For topical application as whole carcinogens, the chemical in 0.1 ml acetone was applied thrice weekly for the duration of the test in the interscapular region. Mice for these tests were shaved at the beginning of the tests and then as needed at regular intervals. In the initiation-promotion experiments, the chemicals were tested as initiators, that is, a single application of initiator followed 2 weeks later by thrice weekly application of PMA at the doses indicated in Table 2 for the duration of the test. For subcutaneous tests the chemicals in 0.05 ml trioctanoin were injected in the left flank once weekly at the doses indicted in Table 2 . Animals were weighed at 30-60-day intervals, and the average body weights of the treated groups were calculated and compared to controls.
Tumor observations were made daily and recorded. Animals that became moribund or died during the treatment period or had large tumor masses were killed by cervical dislocation. All mice were necropsied, and routine sections were taken from the area of administration and also of lung, liver, kidney, spleen, colon, and urinary bladder. All other tissues and organs that appeared clinically abnormal were also taken for histopathology. AH tissues were fixed in formalin, blocked in paraffin, and stained with hematoxylin and eosin for histopathology.
RESULTS
The experimental details and findings from the.present work for three test compounds and the positive control (DMCC) by two routes of administration, skin application and subcutaneous injection, are shown in Table 2 .
The control groups used in these tests gave the expected results: DMCC, which has been tested by us before,(*.-" gave high tumor incidences in all three tests; PMA at the high dose, 0.005 mg per application, resulted in 3 of 30 animals with tumors and n o tumors at the lower dose, 0.0025 mg per application; acetone, used as vehicle for skin application, did not result in any skin tumors in three tests using 110 mice; trioctanoin, the vehicle for subcutaneous injections, resulted in 2 of 130 mice with subcutaneous sarcomas in three tests.
In the two-stage skin application experiments, all three test compounds (DECC, ECF, and DCAC) showed marginally significant incidences of papillomas and squamous carcinomas compared to the PMA control. All three compounds are markedly less active as initiators compared to DMCC in the same test.
Repeated skin application of the acylating agents did not show skin tumorigenicity for ECF and DCAC at doses that resulted in high tumor incidences in DMCC. DECC showed a sharp decrease in carcinogenicity when compared to DMCC in the repeated skin application experiments.
Administration of the compounds in subcutaneous tissue resulted in the same pattern of tumorigenicity as the two-stage skin application tests.
DISCUSSION
The chronic bioassay results presented in Table 2 show decreasing carcinogenic activity in the order: DMCC > DECC > ECF = DCAC. The latter two compounds were inactive as carcinogens by repeated skin application, but the tumor responses when they were tested by subcutaneous injection as well as initiators in two-stage carcinogenesis cannot be disregarded.
The high chemical reactivity of these acylating agents is illustrated by their rapid rates of hydrolysis ( k ) ( Table 1) . These k values are not directly comparable, since they come from different rep o r t~,~~~-~~~ in which either water or water-acetone mixtures in various ratios were used as solvents and at different temperatures (Table 1) . Taking these two factors into consideration, these four compounds can be organized into the decreasing order of rate of hydrolysis: DCAC > DMCC 2 ECF > DECC. From the data presented in Table 1 , it is clear that DCAC hydrolyzes far more rapidly than the other three agents so that its rate of hydrolysis had to be measured at -20°C. (15) The mechanism of hydrolysis, that is, unimolecular nucleophilic substitution (sN1) or bimolecular nucleophilic substitution &2), is as follows: DMCC, S~l ( l~) ; DECC, SNl I"); ECF, S N~( *~' ;
There is no immediately apparent relationship between rate or mechanism of hydrolysis and carcinogenicity in this series, and the same has been found in our earlier studies on SARC.I6.'I Moreover, the nature of the nucleophilic reagent determines whether the mechanism is S N~ or SNZ.('.~~) This point is important with regard to the reactions of acylating, alkylating, and other direct-acting carcinogens with purines, pyrimidines, and other reactive sites on DNA.
Our earlier studies showed that DMCC and DECC react with calf thymus DNA to give mainly the 0 -6 reaction product at the guanine re~idue.1~~1 ECF reacts with adenine under physiological conditions at the N-9 position.('81 It also reacts with adenosine in a nonaqueous medium (pyridine) to give ethyIp~rine-6-carbamate.~~~~ As in the case of rates and mechanisms of hydrolysis, the formation of one or more adducts at specific sites in DNA still does not allow the extrapolation, even qualitatively, to carcinogenicity based on this information alone. This is particularly noteworthy in view of the large number of reactive sites in DNA.18) Very few other acylating carcinogens are known. Two of them are shown in Figure. cinogenicity in this laboratory.l8' Details on that study will be published separately. Benzoyl chloride has been tested in ICR/Ha mice by skin application'lL1 and shown to be weakly carcinogenic.
In an earlier report,'20' we showed that trichlor.oethylene oxide is inactive as a carcinogen by chronic skin application as well as by subcutaneous injection. On the basis of this finding and our earlier negative findings on the carcinogenicity of tri~hloroethylene,'~'~ we questioned'l"' the reported carcinogenicity of this chlorinated ofefin.(z21 However, because of the reported carcinogenicity of trichloroethylene in some bioassays, Loew et recently suggested that DCAC is the "postulated ultimate carcinogen" of trichloroethylene. Their conclusions were based on computerassisted structure-activity studies. The negative results with DCAC presented in this report, however, give additional support to our concerns about the reported carcinogenicity of trichloroethylene.
Because of their high chemical reactivity, none of the compounds discussed in this report are expected to be environmental hazards unless accidentally released in large amounts. For the same reason, they are extensively used in the chemical laboratory. ECF, for example, is used for the modification of DNA bases,'LB1 and DCAC has been used in studies on the mechanisms of reactions of acylating A search of Chemical Abstracts revealed the existence of numerous patents for potential industrial use of DECC. ECF, and DCAC. These patents deal with the use of the acylating agents mainly in the manufacture of agricultural chemicals and pharmaceuticals. The extent to which they are used for these purposes was not ascertained.
